Physician profile
Michael Edward Gates
NPI 1265408348
$7,269.48
in general payments reported to CMS, 2019-2025
28 companies · $747 in 2025
The $747 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,236 · 2020: $521 · 2021: $643 · 2022: $1,066 · 2023: $1,664 · 2024: $1,395 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,804.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,077.30 | 2021-2025 | |
| Pfizer INC. | $1,369.86 | 2019-2025 | |
| Novo Nordisk INC | $1,234.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $678.55 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Allergan, INC. | $296.72 | 2019-2021 | |
| Amgen INC. | $258.83 | 2019-2023 | Aimovig |
| Bayer Healthcare Pharmaceuticals INC. | $256.85 | 2021-2024 | |
| Lilly USA, LLC | $242.49 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Teva Pharmaceuticals USA, INC. | $140.57 | 2022-2024 | Ajovy |
| Lundbeck LLC | $118.96 | 2024-2025 | Vyepti |
| Abbott Laboratories | $103.66 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Ucb, INC. | $80.69 | 2024 | Nayzilam, Briviact |
| Phathom Pharmaceuticals, INC. | $61.73 | 2024 | Voquezna |
| Upsher-Smith Laboratories LLC | $50.42 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $45.21 | 2023-2024 | Farxiga, Airsupra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.23 | 2022 | |
| Edwards Lifesciences Corporation | $33.20 | 2024 | |
| Novartis Pharmaceuticals Corporation | $29.15 | 2019-2022 | |
| Almatica Pharma LLC | $20.53 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.02 | 2021 | |
| Alkermes, INC. | $18.40 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $17.34 | 2025 | Dysport |
| Otter Pharmaceuticals, LLC | $16.98 | 2025 | Sympazan |
| Biohaven Pharmaceutical Holding Company LTD. | $16.58 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.33 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.05 | 2022 | |
| Avanir Pharmaceuticals, INC. | $12.21 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.